Washington State's life sciences industry has seen a remarkable 50% increase in job growth over the past decade, according to the latest Economic Impact Report released by Life Science Washington, the state’s industry trade association. This growth has catapulted Washington into the top 10 life sciences clusters in the United States, surpassing both national life sciences job growth and private sector job growth within the state. As of 2023, Washington’s life sciences sector supports over 118,900 jobs, with more than 47,800 individuals directly employed in the field. Notably, women comprise 45% of the workforce in Washington’s life sciences industry, one of the highest percentages in a STEM-based sector. Marc Cummings, President and CEO of Life Science Washington, attributes this robust growth to a combination of organic expansion and strategic acquisitions by local companies, which have bolstered commercial and manufacturing roles across the state. The industry’s economic impact is significant, contributing $23.1 billion to Washington’s GDP and generating $1.6 billion in local and state tax revenue. The ecosystem encompasses over 1,180 life sciences companies spread across 139 cities, showcasing the widespread support for innovation and research in the region. A key highlight of the 2024 Washington State Investor Report is the substantial increase in investment in the life sciences sector. Total investments reached $2.65 billion in 2024, up from $854.3 million in 2023. This surge in funding is largely due to the rising prominence of AI-driven biotechnology deals. ProfoundBio, a Life Science Washington Institute Washington Innovation Network (WIN) program graduate, secured the largest investment of the year with a $112 million fund raise. Additionally, Genmab A/S’s $1.8 billion acquisition of a local company further underscored the attractiveness of Washington’s biotech scene. Several notable deals involved companies affiliated with the University of Washington’s Institute for Protein Design (IPD), a leader in AI-assisted protein design. Arzeda secured $38 million, Vilya raised $71 million, Archon Biosciences brought in $20 million, and Outpace garnered $144 million. These investments reflect the ongoing support for IPD’s innovative research, which recently won the Nobel Prize in Chemistry for Dr. David Baker’s groundbreaking work on AI-driven protein design. Moreover, established organizations in the state have also contributed to this momentum. The Fred Hutchinson Cancer Center recently formed a $40 million AI alliance with Microsoft and NVIDIA to advance cancer research through the application of large language models and generative AI. Absci, an AI-driven biologics company, sealed a $20 million partnership with AMD to expedite the discovery of new antibody therapeutics. These collaborations demonstrate the deepening integration of AI technologies within the biotech sector and highlight Washington’s growing leadership in this area. Life Science Washington also recognized Madrona Ventures, RA Capital, and ARCH Venture Partners for their 2024 Investor of the Year awards. Each of these firms demonstrated strong commitment to the state’s life sciences ecosystem by making significant investments in at least two Washington-headquartered companies, often leading one of the investment rounds. According to Chris Picardo, Partner at Madrona Ventures, the confluence of world-class research institutions and talented scientists is driving unprecedented innovation in life sciences. “Washington is quickly becoming one of the most exciting places in the world for life sciences innovation,” he stated. “We are proud to back companies like Vilya and Archon Biosciences—emerging from the University of Washington’s Institute for Protein Design—that are translating cutting-edge science into real-world progress.” Peter Kolchinsky, Managing Partner at RA Capital Management, echoed similar sentiments, highlighting the vibrancy of Seattle’s biotech scene and the firm’s pride in funding companies like Icosavax, Outpace, and Profound. “We love Seattle’s vibrant biotech scene and look forward to backing many more of Seattle’s cutting-edge companies,” he said. In summary, Washington’s life sciences industry has demonstrated impressive growth and resilience, driven by a strategic mix of organic expansion, acquisitions, and significant AI investments. This upward trend, paired with the support from leading investors and the recognition of AI-aided research, positions Washington as a pivotal player in the national and global biotech landscape. Industry insiders and observers agree that the synergy between top-tier research institutions and innovative startups is fostering a fertile ground for groundbreaking advancements in biotechnology. Life Science Washington, with its extensive network and advocacy efforts, continues to play a crucial role in nurturing this ecosystem, ensuring that the state remains a hub of life sciences innovation and economic dynamism. Visit Life Science Washington for more detailed reports and insights.